NCT02581228View on ClinicalTrials.gov

Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of Immunotherapy

UnknownOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

April 30, 2018

Study Completion Date

November 30, 2018

Conditions
Melanoma
Interventions
DEVICE

ML-PrediCare

Trial Locations (1)

60991

RECRUITING

Optimata Ltd., Bne ‘Atarot

Sponsors

Lead Sponsor

Optimata Ltd.
All Listed Sponsors
lead

Optimata Ltd.

INDUSTRY

NCT02581228 - Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of Immunotherapy | Biotech Hunter | Biotech Hunter